OSLO, Norway--(BUSINESS WIRE)--Affitech AS, the privately held Norwegian biotechnology company focused on the discovery and development of therapeutic human monoclonal antibodies, announced today that it has signed an agreement with Micromet AG, a biopharmaceutical company developing novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases for a non-exclusive worldwide sub-licenseable research license to the joint patent estate of Micromet and Enzon Pharmaceuticals, Inc. in the field of single-chain antibodies (SCA).
